RedHill Biopharma (RDHL) Total Non-Current Liabilities (2011 - 2025)

RedHill Biopharma (RDHL) has 15 years of Total Non-Current Liabilities data on file, last reported at $1.9 million in Q4 2025.

• On a quarterly basis, Total Non-Current Liabilities rose 268.99% year-over-year to $1.9 million in Q4 2025; TTM through Dec 2025 was $1.9 million, a 268.99% increase from a year earlier, with the FY2025 full-year figure at $1.9 million, up 268.99% from the prior year.
• Total Non-Current Liabilities for Q4 2025 stood at $1.9 million, up from $500000.0 in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for RDHL reached as high as $94.9 million in Q2 2021 and fell as low as $500000.0 in Q2 2025.
• Historically, Total Non-Current Liabilities has averaged $21.7 million across 5 years, with a median of $2.6 million in 2023.
• Across the five-year window, Total Non-Current Liabilities sank 89.86% in 2023 and jumped 268.99% in 2025, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $90.8 million in 2021, then sank by 89.19% to $9.8 million in 2022, then sank by 89.86% to $995000.0 in 2023, then sank by 49.45% to $503000.0 in 2024, then soared by 268.99% to $1.9 million in 2025.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $1.9 million in Q4 2025, $500000.0 in Q2 2025, and $503000.0 in Q4 2024.